Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infant able to attend all study visits~* Parent(s)/legal representative are able to read, understand, and complete study questionnaires~Exclusion Criteria:~* History of congenital or acquired immunodeficiency~* Received or is expected to receive immunosuppressive agents or systemic immunomodulatory steroids~* History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder~* Hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines or concomitant study vaccines~* Has any chronic illness that could interfere with study conduct or completion~* Received any immune globulin, blood, or blood-derived products since birth~* Received a dose of hepatitis B vaccine prior to study entry~* Vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus vaccine, or combination thereof~* Fever within 24 hours prior to enrollment~* Received any non-study vaccine within 30 days prior to enrollment, except for inactivated influenza vaccine, which is permitted 14 days or more prior to enrolment~* Has a coagulation disorder~* Has developmental delay or neurological disorder~* Participant or his/her mother has a medical history of hepatitis B surface antigens (HBsAg) seropositivity~* History of Haemophilus influenzae type b, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, rotavirus gastroenteritis, or invasive pneumococcal infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- PR5I (Type: EXPERIMENTAL): Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.
- INFANRIX™ hexa (Type: ACTIVE_COMPARATOR): Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age \[subset 1\] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age \[subset 2\]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).